One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Can-Fite BioPharma Ltd.
CANF · ASE · Healthcare · Biotechnology
Current price
$1.62
52-week range
$1.50 - $12.40
Market cap
$4.91M
Balance sheet
Healthy
-36.85x Concerning
Net cash $6.99M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Operating margin compressed from -1246.4% to -2316.8% over 3 years.
- Risk Return on equity was -211.4% last year — the company lost money on shareholders' equity.
What this company does
Can-Fite BioPharma Ltd.
Can-Fite BioPharma is a company that is developing new medicines for serious illnesses like cancer and liver disease. They don't make money from selling drugs yet because their medicines are still being tested in clinical trials (research studies on people). Their main focus is on getting these potential new treatments approved by regulators, which could lead to future sales if successful.
How the company got here
Can-Fite BioPharma Ltd. was founded in 1994 as Can-Fite Technologies Ltd. and later changed its name in January 2001. The company is headquartered in Israel and has evolved into a clinical-stage biopharmaceutical firm focused on developing orally bioavailable small molecule drugs. Its core strategy revolves around targeting the A3 adenosine receptor (A3AR), which is found in higher concentrations on inflammatory and cancer cells compared to normal cells. This targeted approach aims to develop treatments for cancer, liver inflammatory diseases, and erectile dysfunction.
What it actually does
Can-Fite BioPharma develops innovative drug candidates that are taken orally, meaning patients can swallow them like a pill. Their main focus is on creating treatments that target a specific biological pathway involving the A3 adenosine receptor (A3AR). This receptor is more active in diseased cells, like those found in cancers or inflammatory conditions, making it a prime target for therapeutic intervention. The company's research and development efforts are concentrated on bringing these potential new medicines through clinical trials to eventually reach patients.
Piclidenoson (CF101)
Piclidenoson is Can-Fite's leading drug candidate, primarily developed for treating psoriasis, a chronic inflammatory skin condition. It has successfully completed Phase III clinical trials, which are large-scale studies in humans to confirm a drug's effectiveness and safety. The company has also out-licensed Piclidenoson to partners in various regions, including Canada, Europe, and Asia, for its development and commercialization. Additionally, Piclidenoson is being explored for other conditions, including osteoarthritis in pets through a partnership with Vetbiolix.
Namodenoson (CF102)
Namodenoson is another key drug candidate in Can-Fite's pipeline, targeting serious diseases like liver cancer (hepatocellular carcinoma), pancreatic cancer, and metabolic-associated steatohepatitis (MASH), a liver condition. It is currently undergoing pivotal Phase III clinical trials for liver cancer and has shown promise in Phase II trials for pancreatic cancer and MASH. Namodenoson has received special designations like Orphan Drug and Fast Track from regulatory bodies, which can help speed up its development and review process. The company has also entered into licensing agreements for Namodenoson's development and commercialization.
CF602
CF602 is Can-Fite's drug candidate being investigated for the treatment of erectile dysfunction. This drug has demonstrated efficacy in pre-clinical studies, which are studies conducted before human trials. The company is exploring its potential to treat sexual dysfunction, particularly in patients who may not respond to existing treatments. Patent protection for CF602 has been secured in Brazil, indicating progress in its development for this specific medical need.
Cannabinoids and Biomarker Tests
Beyond its named drug candidates, Can-Fite BioPharma is also researching the use of cannabinoids for conditions linked to elevated A3 adenosine receptor activity. This involves exploring how compounds found in cannabis might be used therapeutically. Furthermore, the company is developing a commercial predictive biomarker blood test kit designed to identify patients with specific A3AR expressions, which could help in tailoring treatments more effectively.
What management is betting on now
Can-Fite's management is strategically focused on advancing its lead drug candidates, Piclidenoson and Namodenoson, through late-stage clinical trials (Phase III) towards potential regulatory approval. They are actively seeking global licensing and strategic partnerships to commercialize these assets, leveraging existing agreements and pursuing new collaborations. The company is also focused on expanding its intellectual property portfolio to protect its innovations and exploring new therapeutic applications for its platform technology.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-7.64M
FY2025 Q4
$-8.95M
Revenue
$405.00K
Net income
$-9.83M
Diluted EPS
-5.97
Operating cash flow
$-8.95M
Free cash flow
$-8.95M
Fetching…
Sources
Revenue
$674.00K
Net income
$-7.88M
Diluted EPS
0.00
Operating cash flow
$-7.64M
Free cash flow
$-7.64M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.62
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $7.0M - more cash than debt. Interest coverage -36.9x.
Net debt
$-6.99M
Interest coverage
-36.85x
Can-Fite BioPharma Ltd. is healthier than 0 of 1 peers on balance-sheet leverage.
Healthy
Worse cushion
Baseline
Better cushion
CANF
BASELINE
Can-Fite BioPharma Ltd.
Total debt $49.00K Interest coverage -36.85x This is the baseline the peer rows are being compared against.
What you should know
The case for and against CANF
0 Rewards
2 Risks
Rewards
Risks
-
Operating margin compressed from -1246.4% to -2316.8% over 3 years.
-
Return on equity was -211.4% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.78x
P/B
0.71x
P/S
12.13x
EV/EBITDA
0.37x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
100.0%
Operating margin
-2,316.8%
Net margin
0.0%
ROE
-211.4%
ROA
-77.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.01x
Current ratio
3.60x
Quick ratio
3.17x
Total debt
$49.00K
Total cash
$7.04M
Growth
How the business has been compounding
Revenue TTM
$2.63M
Revenue 5Y CAGR
-17.0%
EPS TTM
-13.23
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-35.83M
Free CF TTM
$-8.95M
FCF margin
-340.1%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—